Kamada Ltd. Stock

Equities

KMDA

IL0010941198

Pharmaceuticals

Market Closed - TEL AVIV STOCK EXCHANGE 10:24:31 2024-05-30 am EDT 5-day change 1st Jan Change
1,934 ILa +1.31% Intraday chart for Kamada Ltd. +0.89% -13.16%

Financials

Sales 2024 * 592M 160M 59.18B Sales 2025 * 665M 179M 66.52B Capitalization 1.11B 300M 111B
Net income 2024 * 53M 14.3M 5.3B Net income 2025 * 63M 16.99M 6.3B EV / Sales 2024 * 1.88 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.67 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 378
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.25%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.31%
1 week+0.89%
1 month-2.52%
3 months-15.06%
6 months+12.90%
Current year-13.16%
More quotes
1 week
1 882.00
Extreme 1882
1 948.00
1 month
1 882.00
Extreme 1882
2 200.00
Current year
1 872.00
Extreme 1872
2 338.00
1 year
1 685.00
Extreme 1685
2 338.00
3 years
1 309.00
Extreme 1309
2 338.00
5 years
1 309.00
Extreme 1309
4 500.00
10 years
1 160.00
Extreme 1160
4 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 13-12-08
Founder 73 90-12-12
Director of Finance/CFO 53 17-12-30
Members of the board TitleAgeSince
Director/Board Member 62 19-12-23
Director/Board Member 76 05-04-30
Founder 73 90-12-12
More insiders
Date Price Change Volume
24-05-30 1,934 +1.31% 19,138
24-05-29 1,909 +0.79% 15,143
24-05-28 1,894 -1.41% 63,507
24-05-27 1,921 +0.10% 18,143
24-05-26 1,919 +0.10% 12,364

Delayed Quote TEL AVIV STOCK EXCHANGE, May 30, 2024 at 10:24 am EDT

More quotes
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
More about the company

Quarterly revenue - Rate of surprise